CoChat

Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1

Open access
Ogihara, Toshio, Saruta, Takao, Rakugi, Hiromi, Saito, Ikuo, Shimamoto, Kazuaki, Matsuoka, Hiroaki, Shimada, Kazuyuki, Ito, Sadayoshi, Horiuchi, Masatsugu, Imaizumi, Tsutomu, Takishita, Shuichi, Higaki, Jitsuo, Katayama, Shigehiro, Kimura, Genjiroh, Umemura, Satoshi, Ura, Nobuyuki, Hayashi, Koichi, Odawara, Masato, Tanahashi, Norio, Ishimitsu, Toshihiko, Kashihara, Naoki, Morita, Satoshi, Teramukai, Satoshi · 2014 · Journal of Hypertension
Cited by 48

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The aim of the present study was to compare the cardiovascular effects of olmesartan, an angiotensin II receptor blocker, combined with a calcium channel blocker (CCB) or a diuretic, in a prospective, randomized, open-label, blinded endpoint trial. METHODS: Japanese hypertensive patients aged at least 65 to less than 85 years with SBP at least 140 mmHg and/or DBP at least 90 mmHg with antihypertensive treatment, or SBP at least 160 mmHg and/or DBP at least 100 mmHg without antihypertensive treatment were randomized to receive olmesartan with either a dihydropyridine CCB or a low-dose diuretic. If SBP and/or DBP remained at least 140 and/or at least 90 mmHg, the other antihypertensive drug was added. The primary endpoint was a composite of fatal and nonfatal cardiovascular events. The median follow-up time was 3.3 years. RESULTS: Blood pressure decreased similarly in both groups. The primary endpoint occurred in 116/2568 patients (4.5%) in the olmesartan plus CCB group and in 135/2573 patients (5.3%) in the olmesartan plus diuretic group [hazard ratio 0.83, 95% confidence interval (CI) 0.65-1.07, P = 0.16]. Rates of all-cause death and cardiovascular deaths were similar. Among patients aged at least 75 years, the incidence of stroke tended to be lower in the olmesartan plus CCB group than in the olmesartan plus diuretic group (hazard ratio 0.63, 95% CI 0.38-1.02, P = 0.059, interaction P = 0.019). Fewer patients in the olmesartan plus CCB group (8.2%, 211/2568) than in the olmesartan plus diuretic group (9.8%, 253/2573; P = 0.046) experienced serious adverse events. CONCLUSION: Despite no significant difference in cardiovascular events, the different safety profiles suggest that the combination of olmesartan and CCB may be preferable to that of olmesartan and diuretic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000000281

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 48

Metadata

Authors
Ogihara, T., Saruta, T., Rakugi, H., Saito, I., Shimamoto, K., Matsuoka, H., Shimada, K., Ito, S., Horiuchi, M., Imaizumi, T., Takishita, S., Higaki, J., Katayama, S., Kimura, G., Umemura, S., Ura, N., Hayashi, K., Odawara, M., Tanahashi, N., Ishimitsu, T., Kashihara, N., Morita, S., & Teramukai, S.
Venue
Journal of Hypertension
Published
2014-10
Volume
32
Issue
10
Pages
2054-2063
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2050003957
Cited by
48
References
6
FWCI
4.21
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1. https://app.cochat.ai/papers/10.1097/hjh.0000000000000281
The paper
Ogihara, T., Saruta, T., Rakugi, H., Saito, I., Shimamoto, K., Matsuoka, H., Shimada, K., Ito, S., Horiuchi, M., Imaizumi, T., Takishita, S., Higaki, J., Katayama, S., Kimura, G., Umemura, S., Ura, N., Hayashi, K., Odawara, M., Tanahashi, N., . . . Teramukai, S. (2014). Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000281

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.